GSK plc (LSE/NYSE: GSK) has announced completion of its acquisition of Nuvalent, Inc.1, a Boston-based clinical-stage biopharmaceutical company focused on creating precisely targeted oncology therapies. The acquisition adds three lung cancer assets to GSK’s oncology portfolio. Zidesamtinib (NVL-520) and neladalkib (NVL-655) are considered potential best-in-class assets, based on clinical data, and are under FDA review for ROS1-positive and ALK-altered non-small cell lung cancer (NSCLC) with target decision dates later this year. The aggregate equity value of the transaction is approximately $10.6 billion (£8.0 billion).
Read the full article: GSK Completes Acquisition of Nuvalent, Inc. //
Source: https://www.gsk.com/en-gb/media/press-releases/gsk-completes-acquisition-of-nuvalent-inc/